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Abstract 
Purpose: To investigate the anti-hyperPRL mechanism of traditional Chinese medicine Huiru Decoction 
(HD) in rats.  
Methods: The effect of HD on serum prolactin (PRL), estradiol (E2), progesterone   (PGN), follicle 
stimulating hormone (FSH) and luteinizing hormone (LH) levels were investigated in hyperprolactinemia 
(hyperPRL) rats. Furthermore, the effect of HD on hypothalamus dopamine D2 receptor, protein kinase 
A (PKA) and cyclic adenosine monophosphate (cAMP) levels of hyperPRL rats were investigated 
respectively. 
Results: Compared with the model group, a high dose of HD (19.2 g/kg body weight) and medium dose 
of HD (9.6 g/kg body weight) reduced PRL level of hyperPRL rats effectively (p < 0.01). HD increased 
dopamine D2 receptor (p < 0.01), reduced cAMP (p < 0.01) and PKA (p < 0.01) levels of hypothalamus 
in hyperPRL rats significantly.  
Conclusions: HD showed anti-hyperPRL activity via dopamine D2 receptor. 
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Hyperprolactinemia, which is one of the most 
common endocrine disorders of the 
hypothalamus-pituitary axis (PRL > 25ng/mL) in 
young women, is associated with galactorrhea 
and ovulatory dysfunction that results in 
menstrual irregularities [1]. HyperPRL can occur 
at any age, and the prevalence varies from 0.4 % 
in the normal adult population to as high as 9-17 
% in women with menstrual problems such as 
amenorrhea or polycystic ovarian syndrome 
[2,3]. Common causes which induce hyperPRL 
are hypothalamus-pituitary lesions, pituitary 
tumor, severe liver or kidney disease, neuritis or 
irritations of the spinal cord, depression or other 
physiological factors such as pregnancy and 
lactation [4,5]. Galactorrhea is a common kind of 
female disease induced by hyperPRL. Synthetic 
drugs are used in treating them, but they always 
bring many side effects such as menstrual 
disorder and the relapse rate is very high. 
Bromocriptine and cabergoline are effective in 
curing hyperPRL, but 12 % patients cannot 
endure bromocriptine [6]. 
 
Empirical evidence suggests that many herbal 
medicines possess the therapeutic potential to 
alleviate hyperPRL symptoms [8]. In China, Huiru 
Decoction (HD) is composed of Chai Hu 
(Bupleurum chinense DC.) 60 g, Xia Ku Cao 
(Prunella vulgaris L.) 15 g, Xiangfu (Cyperus 
rotundus L.) 12 g, Danpi (Tree Peony Bark) 10g, 
Gancao (Glycyrrhiza uralensis Fisch) 10g and 
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Dan Shen (Salvia miltiorrhiza Bge.) 10 g. It is 
often used to treat galactorrhea effectively 
without toxic side effect. In previous study, we 
found that HD could decrease prolactin level in 
hyperPRL mice effectively [9]. However, the anti-
hyperPRL mechanism of it was still unknown. 
 
In order to clarify the mechanisms underlying the 
anti-hyperPRL effects of HD, we planned a direct 
experimental test. Most conventional anti-
hyperPRL agents reduce PRL secretion through 
D2 receptor agonism in the hypothalamic 
neuroendocrine dopaminergic system, and 
cAMP/PKA signal transduction pathway is one of 
dopamine receptor classic pathways [10]. And 
other sex-steroids other than PRL and DAT are 
also involved in the pathophysiology of hyperPRL 
[11]. Therefore, we hypothesized that the 
therapeutic efficacy of HD in alleviating 
hyperPRL could be attributed to modulation of 
dopamine D2 receptor. To test this hypothesis, 
we examined the effects of HD on dopamine D2 





Preparation of HD 
 
The dried herbs of HD were decocted with 1000 
ml water twice, 45 min for each. Then the liquor 
was filtrated by a funnel and concentrated into 
200 ml of HD. The HD was used for animal 
experiments. 
 
Experiment in animal model of hyperPRL 
 
Female Wistar rats weighing 200-220 g were 
obtained from Jiangsu Center for Disease 
Control and Prevention, Nanjing, Jiangsu. The 
animals had free access to food and water, and 
were allowed to acclimatize for at least one week 
before use. All experiments were approved by 
the Animal Care and Use Committee and were 
carried in compliance with the Animal Welfare 
Act and the NIH guidelines (NIH publication 
No.80-23, revised 1996). 
 
Rats were given intraperitoneal (i.p.) of 
metoclopramide (MCP, 150 mg/kg daily) for 10 
days to prepare hyperPRL model [12]. 60 rats 
were divided into six groups of ten individuals: 
control, model group, model plus positive drug 
bromocriptine group, plus high dose of HD (19.2 
g/kg) group, plus middle dose of HD (9.6 g/kg) 
group and plus low dose of HD (4.8 g/kg) group. 
Each dose was dissolved in 2 mL of water, and 
given into rats by administered gavage. The 
dosage was calculated from the daily human 
AFH clinical dosage based on body surface area. 
Control and model rats received 2 ml of water. All 
group mice were intragastric administrated for 30 
days. 
 
Sex hormones determination 
 
After the treatment of administrating for 30 days 
in hyperPRL rats, serum was obtained by eyeball 
removal. Serum PRL, E2, PGN, FSH and LH 
levels of the rats were measured by ELISA kits 
(Shenzhen Xin-Bo-Sheng Biological Technology 
Co., Ltd., China). 
 
Western blot analysis of hypothalamus 
dopamine D2 receptor 
 
Rat hypothalamus tissues were homogenized in 
10 wt/vol RIPA buffer with protease inhibitor and 
centrifuged at 3000×g for 15 min at 4 oC. The 
supernatant samples were centrifuged at 12,000 
× g for 20 min at 4 oC. The final peptides were 
dissolved in a RIPA buffer and loading buffer. 
After resolution of hypothalamus protein (equal 
loading for each sample) by 12 % sodium 
dodecyl sulfate polyacryla-mide gel 
electrophoresis, the protein samples were 
transferred onto polyvinylidene difluoride 
membranes (Merck), respectively. Nonspecific 
protein-binding sites were blocked with 
phosphate-buffered saline containing 0.1 % 
Tween-20 and 5 % fat-free milk for 1 h at room 
temperature, and then incubated in appropriate 
primary antibodies (DRD2, 1: 1000; ß-actin, 1: 
5000).  Immunoreactive bands were visualized 
by incubation with lumiGLO reagent (Cell 
Signaling) and exposed to X-ray film (Kodak, 
Stamford, CT, USA). Quantification of Western 
blot analysis was performed with ImageJ 
(National Institutes of Health, Bethesda, MD, 
USA). ß-actin levels were used as a protein 
loading control. The relative levels of target 
proteins were determined after normalization with 
ß-actin, respectively. 
 
Measurement of hypothalamus PKA and 
cAMP levels 
 
Rat brains were stripped and grinded into 
homogenate, then centrifugated for 15 min at 
3000 r·min-1. The supernatant was used to 
measure PKA and cAMP levels by ELISA kits 
(Shenzhen Xin-Bo-Sheng Biological Technology 




Values are expressed as mean ± SEM. 
Significant differences between the groups were 
analyzed using one-way analysis of variance 
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(ANOVA) followed by two-paired Student’s t-test. 




Effect of HD on sex hormones in rat model of 
hyperPRL 
 
Compared with control group, serum PRL level of 
hyperPRL model rats increased significantly (p < 
0.01). Serum E2, PGN and FSH and LH (p < 
0.05) levels of hyperPRL model rats decreased 
significantly (p < 0.01). Compared with model 
group, the increased PRL level was significantly 
attenuated by treatment with 0.6 mg/kg 
bromocriptine and 9.6 or 19.2 g/kg HD after 30 
days (p < 0.01). And rat serum E2 level 
decreased (p < 0.01), and serum PGN, FSH and 
LH levels increased (p < 0.05) effectively in 
bromocriptine-treated group. Compared with 
model group, rat serum E2 level decreased (p < 
0.01), and serum P, FSH and LH levels 
increased (p < 0.05) significantly treated by high-
dose of HD (Table 1). 
 
Effects of HD on hypothalamus dopamine D2 
receptor in rat model of hyperPRL 
 
Western blot analysis revealed that 
hypothalamus dopamine D2 receptor protein 
expression in model rats was much less than that 
in control rats (p < 0.01). Compared with model 
rats, such decreased dopamine D2 receptor 
protein were significantly improved by treatment 
with 0.6 mg/kg bromocriptine (p < 0.01) or 4.8 
g/kg (p < 0.05) or 9.6 g/kg (p < 0.01) or 19.2 g/kg 
(p < 0.01) HD for 30 days. 
 
Effect of HD on hypothalamus PKA and cAMP 
levels in rat model of hyperPRL  
 
Our study demonstrated that hypothalamus PKA 
(p < 0.01) and cAMP (p < 0.01) level in rat model 
of hyperPRL increased significantly compare to 
control group. Such increased PKA and cAMP 
were significantly attenuated by treatment with 
0.6 mg/kg bromocriptine or 4.8 g/kg (p <0.05) or 
9.6 g/kg (p < 0.01) or 19.2 g/kg (p < 0.01) HD for 




In previous study, we found that HD could 
decrease prolactin level in hyperPRL rats 
effectively. In this study, HD increased dopamine 
D2 receptor, reduced the hypothalamus cAMP 
and PKA levels in hyperPRL rats significantly. 
 
Dopamine receptors belong to the family of 
seven transmembrane domain G-protein coupled 
receptors (GPCR) [13-15]. Dopamine receptors 
D1 and D2 are classified into two subfamilies 
based on their differential effect on adenylyl 
cyclase. 
 
Classically, the functions of dopamine receptors 
have been associated with the regulation of 
adenylate cyclase-protein kinas A (cAMP–PKA) 
through G-protein-mediated signaling. Two 
classes of GPCR mediate dopamine functions, 
D1-like receptor subtypes (D1 and D5) couple 
mostly to Gas and stimulate the production of the 
second messenger cAMP and the activity of 
PKA. However, D2-like subfamily (D2, D3, and 
D4) couple to Gai/o and regulate the production 
of cAMP negatively, thus resulting in a diminution 
of PKA activity [16-18].  
 
Table 1: Effect of HD on sex hormones in hyperPRL rats 
 









Control  201.17 ± 6.35  3.74± 0.31  1.37 ± 0.06  0.98 ± 0.06  1.86 ± 0.16  
Model  453.22±32.43**  1.46 ± 0.14**  0.53 ± 0.12**  
0.41 ± 
0.04**  0.88 ± 0.08
*  
Bromocriptine  224.54±10.62△  2.83 ± 0.26△△  0.84 ± 0.05△  
0.77 ± 
0.03△  1.62 ± 0.07
△  
HD-H  221.16±12.36△ 2.59 ± 0.18△△  0.88 ± 0.06△  0.63± 0.04
△  1.76 ± 0.24△  
HD-M  257.52±13.48△ 2.41 ± 0.34△  0.79 ± 0.04△  0.65± 0.03
△  1.58± 0.06△  
HD-L  318.27 ± 45.48  1.86 ± 0.45  0.60 ± 0.12  0.57 ± 0.05  1.23 ± 0.16  
Data are expressed as mean ± SEM (n =10) and analyzed using one-way ANOVA. *p < 0.05 and **p < 0.01 
versus control group; △p < 0.05 and △△p < 0.01 versus model group. HD-H: High-dose of HD; HD-M: Mid-dose of 
HD; HD-L: Low-dose of HD 
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Figure 1: Effect of HD on hypothalamus PKA and cAMP levels in hyperPRL rats. Data are expressed as mean ± 
SEM (n = 10) and analyzed using one-way ANOVA.  *p < 0.05 and **p < 0.01 versus model group 
 
The physiological and pathological roles of DR2 
have been recognized in some organs such as 
brain and kidney [19,20]. In the 
adenohypophysis, the predominant dopamine 
receptor is the D2 receptor [21]. Transfection of 
the dopamine D2 receptor into a pituitary cell line 
results in a decrease in intracellular cAMP and 
inhibits prolactin secretion when dopamine is 
added to the cell culture [22,23]. Most 
conventional anti-hyperPRL agents reduce PRL 
secretion through D2 receptor agonism in the 
hypothalamic neuroendocrine dopaminergic 
system, and cAMP/PKA signal transduction 
pathway is one of dopamine receptor classic 
pathways. In our study, HD inhibited PRL level 
via dopamine D2 receptor, and it reduced the 
cAMP and PKA levels of hypothalamus in 
hyperPRL rats significantly. These suggested 
that HD showed anti-hyperPRL activity via 




Our studies demonstrated that HD show anti-
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